Oncotalks hematology videos and news

EHA 2019 Prof. Michael Pfeilstöcker, MD

Prof. Michael Pfeilstöcker, MD from the Heinrich-Heine University Hospital, Düsseldorf, Germany is commenting on 2 publications

  • LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE US EXPLORYS AND MARKETSCAN DATABASES

Reference: EHA Library. Bussel J. Jun 14, 2019; 266509
Link to abstract: https://library.ehaweb.org/eha/2019/24th/266509/j.bussel.long-term.overuse.of.corticosteroids.in.the.real-world.treatment.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DLONG-TERM+OVERUSE+OF+CORTICOSTEROIDS+IN+THE+REAL-WORLD+TREATMENT+OF+PATIENTS+WITH+IMMUNE+THROMBOCYTOPENIA+IN+THE+US+EXPLORYS+AND+MARKETSCAN+DATABASES

  • DIFFERENCES IN PERCEPTIONS ON TREATMENT APPROACHES BETWEEN PHYSICIANS AND ITP PATIENTS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) both presented at EHA 2019 in Amsterdam

Reference: EHA Library. Kruse A. Jun 14, 2019; 266510
Link to abstract: https://library.ehaweb.org/eha/2019/24th/266510/alexandra.kruse.differences.in.perceptions.on.treatment.approaches.between.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dresults%2Bitp+world+impact+survey+%28i-wish

Related items

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania
00:03:29
EHA 2019 Jeroen Janssen, MD, PhD

EHA 2019 Jeroen Janssen, MD, PhD

Jeroen Janssen MD, PhD from the Amsterdam UMC, Amsterdam, The Netherlands is commenting on the abstract COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) & COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA Reference: EHA Library. Kew S. Jun 15, 2019; 267467Link to abstract: https://library.ehaweb.org/eha/2019/24th/267467/sam.kew.combination.of.asciminib.plus.nilotinib.28nil29.or.dasatinib.28das29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dasciminib
EHA , Latvia , Lithuania , Estonia , Albania
00:05:04
ASCO 2019 Prof. Dirk Schadendorf, MD

ASCO 2019 Prof. Dirk Schadendorf, MD

Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)
ASCO , Latvia , Lithuania , Estonia , Hungary , Albania
00:10:57